Dana Investment Advisors Inc. cut its stake in Stryker Corporation (NYSE:SYK) by 1.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,058 shares of the medical technology company’s stock after selling 3,387 shares during the period. Stryker accounts for about 1.4% of Dana Investment Advisors Inc.’s portfolio, making the stock its 20th largest position. Dana Investment Advisors Inc. owned about 0.06% of Stryker worth $30,259,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Marco Investment Management LLC raised its position in Stryker by 10.4% during the 3rd quarter. Marco Investment Management LLC now owns 70,875 shares of the medical technology company’s stock worth $10,066,000 after buying an additional 6,685 shares during the last quarter. Baker Chad R raised its position in Stryker by 3.9% during the 3rd quarter. Baker Chad R now owns 18,070 shares of the medical technology company’s stock worth $2,567,000 after buying an additional 670 shares during the last quarter. Guardian Capital LP raised its position in Stryker by 4.1% during the 3rd quarter. Guardian Capital LP now owns 124,492 shares of the medical technology company’s stock worth $17,680,000 after buying an additional 4,849 shares during the last quarter. Piedmont Investment Advisors LLC raised its position in Stryker by 0.9% during the 3rd quarter. Piedmont Investment Advisors LLC now owns 77,882 shares of the medical technology company’s stock worth $11,061,000 after buying an additional 707 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Stryker by 5.5% during the 3rd quarter. California Public Employees Retirement System now owns 762,555 shares of the medical technology company’s stock worth $108,298,000 after buying an additional 40,029 shares during the last quarter. Institutional investors own 74.97% of the company’s stock.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.40% of the stock is currently owned by insiders.

Shares of Stryker Corporation (NYSE:SYK) traded up $0.96 during midday trading on Wednesday, reaching $153.67. 1,078,000 shares of the company traded hands, compared to its average volume of 1,177,003. The stock has a market cap of $57,149.83, a price-to-earnings ratio of 24.20, a PEG ratio of 2.40 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker Corporation has a 12 month low of $116.27 and a 12 month high of $160.62.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The firm’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.39 EPS. research analysts predict that Stryker Corporation will post 6.47 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. Stryker’s payout ratio is presently 36.32%.

A number of research firms have issued reports on SYK. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Thursday, December 7th. Royal Bank of Canada reissued a “buy” rating and set a $155.00 price target on shares of Stryker in a research report on Monday, October 2nd. BMO Capital Markets raised shares of Stryker to a “market perform” rating and set a $163.00 price target for the company in a research report on Tuesday. BidaskClub raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $161.00 target price on shares of Stryker in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $153.19.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/stryker-corporation-syk-position-reduced-by-dana-investment-advisors-inc/1761778.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with Analyst Ratings Network's FREE daily email newsletter.